Imaging outcomes for trials of remyelination in multiple sclerosis

Shahrukh Mallik, Rebecca S Samson, Claudia A M Wheeler-Kingshott, David H Miller, Shahrukh Mallik, Rebecca S Samson, Claudia A M Wheeler-Kingshott, David H Miller

Abstract

Trials of potential neuroreparative agents are becoming more important in the spectrum of multiple sclerosis research. Appropriate imaging outcomes are required that are feasible from a time and practicality point of view, as well as being sensitive and specific to myelin, while also being reproducible and clinically meaningful. Conventional MRI sequences have limited specificity for myelination. We evaluate the imaging modalities which are potentially more specific to myelin content in vivo, such as magnetisation transfer ratio (MTR), restricted proton fraction f (from quantitative magnetisation transfer measurements), myelin water fraction and diffusion tensor imaging (DTI) metrics, in addition to positron emission tomography (PET) imaging. Although most imaging applications to date have focused on the brain, we also consider measures with the potential to detect remyelination in the spinal cord and in the optic nerve. At present, MTR and DTI measures probably offer the most realistic and feasible outcome measures for such trials, especially in the brain. However, no one measure currently demonstrates sufficiently high sensitivity or specificity to myelin, or correlation with clinical features, and it should be useful to employ more than one outcome to maximise understanding and interpretation of findings with these sequences. PET may be less feasible for current and near-future trials, but is a promising technique because of its specificity. In the optic nerve, visual evoked potentials can indicate demyelination and should be correlated with an imaging outcome (such as optic nerve MTR), as well as clinical measures.

Keywords: MRI; Multiple Sclerosis.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Figures

Figure 1
Figure 1
Axial view of slices of the brain of a multiple sclerosis patient demonstrating appearance on (A) T2w imaging and (B) magnetisation transfer ratio (MTR) map of the corresponding slice. The red box contains a lesion which is markedly hypointense compared with normal appearing white matter (NAWM), hence corresponding to a low MTR value in the lesion, and compatible with demyelination. The green box contains three lesions which appear isointense or only slightly hypointense compared with NAWM, hence corresponding to higher lesion MTR (similar to or slightly less than NAWM), suggesting possible remyelination.

References

    1. Barkhof F, Calabresi PA, Miller DH, et al. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol 2009;5:256–66.
    1. Bitsch A, Kuhlmann T, Stadelmann C, et al. A Longitudinal MRI Study of Histopathologically Defined Hypointense Multiple Sclerosis Lesions. Ann Neurol 2001;49:793–6.
    1. Van Walderveen MA, Kamphorst W, Scheltens P, et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998;50:1282–8
    1. Vavasour IM, Laule C, Li DKB, et al. Is the magnetization transfer ratio a marker for myelin in multiple sclerosis? J Magn Reson Imaging 2011;33:713–8.
    1. Schmierer K, Scaravilli F, Altmann DR, et al. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol 2004;56:407–15.
    1. Filippi M, Campi A, Dousset V, et al. A magnetization transfer imaging study of normal-appearing white matter in multiple sclerosis. Neurology 1995;45: 478–82
    1. Barkhof F, Brück W, De Groot CJ, et al. Remyelinated lesions in multiple sclerosis. Arch Neurol 2003;60:1073–81.
    1. Chen JT, Collins DL, Atkins HL, et al. Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Ann Neurol 2008;63:254–62.
    1. Cercignani M, Symms MR, Schmierer K, et al. Three-dimensional quantitative magnetisation transfer imaging of the human brain. Neuroimage 2005;27:436–41.
    1. Levesque IR, Sled JG, Narayanan S, et al. Reproducibility of quantitative magnetization-transfer imaging parameters from repeated measurements. Magn Reson Med 2010;64:391–400.
    1. Schmierer K, Wheeler-kingshott CAM, Tozer DJ, et al. Quantitative magnetic resonance of post mortem multiple sclerosis brain before and after fixation. Magn Reson Med 2008;59:268–77.
    1. Ou X, Sun S-W, Liang H-F, et al. Quantitative magnetization transfer measured pool-size ratio reflects optic nerve myelin content in ex vivo mice. Magn Reson Med 2009;61:364–71.
    1. Giacomini PS, Levesque IR, Ribeiro L, et al. Measuring demyelination and remyelination in acute multiple sclerosis lesion voxels. Arch Neurol 2009;66:375–81.
    1. MacKay A, Whittall K, Adler J, et al. In vivo visualization of myelin water in brain by magnetic resonance. Magn Reson Med 1994;31:673–7
    1. Laule C, Kozlowski P, Leung E, et al. Myelin water imaging of multiple sclerosis at 7 T: correlations with histopathology. Neuroimage 2008;40:1575–80.
    1. Gareau PJ, Rutt BK, Karlik SJ, et al. Magnetization transfer and multicomponent T2 relaxation measurements with histopathologic correlation in an experimental model of MS. J Magn Reson Imaging 2000;11:586–95
    1. Vavasour IM, Whittall KP, Li DK, et al. Different magnetization transfer effects exhibited by the short and long T(2) components in human brain. Magn Reson Med 2000;44:860–6
    1. Nguyen TD, Wisnieff C, Cooper M a, et al. T2 prep three-dimensional spiral imaging with efficient whole brain coverage for myelin water quantification at 1.5 tesla. Magn Reson Med 2012;67:614–21.
    1. Prasloski T, Rauscher A, MacKay AL, et al. Rapid whole cerebrum myelin water imaging using a 3D GRASE sequence. Neuroimage 2012;63:533–9.
    1. Kolind S, Matthews L, Johansen-Berg H, et al. Myelin water imaging reflects clinical variability in multiple sclerosis. Neuroimage 2012;60:263–70.
    1. Deoni SCL, Rutt BK, Arun T, et al. Gleaning multicomponent T1 and T2 information from steady-state imaging data. Magn Reson Med 2008;60:1372–87.
    1. Lankford CL, Does MD. On the inherent precision of mcDESPOT. Magn Reson Med 2013;69:127–36.
    1. Pierpaoli C, Barnett a, Pajevic S, et al. Water diffusion changes in Wallerian degeneration and their dependence on white matter architecture. Neuroimage 2001;13:1174–85.
    1. Gouw AA, Seewann A, Vrenken H, et al. Heterogeneity of white matter hyperintensities in Alzheimer's disease: post-mortem quantitative MRI and neuropathology. Brain 2008;131:3286–98.
    1. Schmierer K, Wheeler-Kingshott C a M, Boulby P a, et al. Diffusion tensor imaging of post mortem multiple sclerosis brain. Neuroimage 2007;35:467–77.
    1. Song S-K, Yoshino J, Le TQ, et al. Demyelination increases radial diffusivity in corpus callosum of mouse brain. Neuroimage 2005;26:132–40.
    1. Song S-K, Sun S-W, Ramsbottom MJ, et al. Dysmyelination revealed through MRI as increased radial (but unchanged axial) diffusion of water. Neuroimage 2002;17:1429–36.
    1. Laule C, Vavasour IM, Kolind SH, et al. Magnetic resonance imaging of myelin. Neurotherapeutics 2007;4:460–84.
    1. Wheeler-Kingshott C a M, Cercignani M. About “axial” and “radial” diffusivities. Magn Reson Med 2009;61:1255–60.
    1. Wheeler-kingshott CAM, Ciccarelli O, Schneider T, et al. A new approach to structural integrity assessment baesd on axial and radial diffusivities. Funct Neurol 2012;27:85–90.
    1. Wang Y, Wang Q, Haldar JP, et al. Quantification of increased cellularity during inflammatory demyelination. Brain 2011;134:3590–601.
    1. Zhang H, Schneider T, Wheeler-Kingshott C a, et al. NODDI: practical in vivo neurite orientation dispersion and density imaging of the human brain. Neuroimage 2012;61:1000–16.
    1. Jespersen SN, Bjarkam CR, Nyengaard JR, et al. Neurite density from magnetic resonance diffusion measurements at ultrahigh field: comparison with light microscopy and electron microscopy. Neuroimage 2010;49:205–16.
    1. Stankoff B, Wang Y, Bottlaender M, et al. Imaging of CNS myelin by positron-emission tomography. Proc Natl Acad Sci USA 2006;103:9304–9.
    1. Stankoff B, Freeman L, Aigrot M-S, et al. Imaging central nervous system myelin by positron emission tomography in multiple sclerosis using [methyl-11C]-2-(4′-methylaminophenyl)- 6-hydroxybenzothiazole. Ann Neurol 2011;69:673–80.
    1. DeLuca GC, Williams K, Evangelou N, et al. The contribution of demyelination to axonal loss in multiple sclerosis. Brain 2006;129:1507–16.
    1. Stroman PW, Wheeler-Kingshott C, Bacon M, et al. The current state-of-the-art of spinal cord imaging: methods. Neuroimage 2014;84:1070–81.
    1. Hickman SJ, Hadjiprocopis A, Coulon O, et al. Cervical spinal cord MTR histogram analysis in multiple sclerosis using a 3D acquisition and a B-spline active surface segmentation technique. Magn Reson Imaging 2004;22:891–5.
    1. Mottershead JP, Schmierer K, Clemence M, et al. High field MRI correlates of myelin content and axonal density in multiple sclerosis--a post-mortem study of the spinal cord. J Neurol 2003;250:1293–301.
    1. Zackowski KM, Smith SA, Reich DS, et al. Sensorimotor dysfunction in multiple sclerosis and column-specific magnetization transfer-imaging abnormalities in the spinal cord. Brain 2009;132:1200–9.
    1. Smith SA, Golay X, Fatemi A, et al. Magnetization transfer weighted imaging in the upper cervical spinal cord using cerebrospinal fluid as intersubject normalization reference (MTCSF imaging). Magn Reson Med 2005;54:201–6.
    1. Klawiter EC, Schmidt RE, Trinkaus K, et al. Radial diffusivity predicts demyelination in ex vivo multiple sclerosis spinal cords. Neuroimage 2011; 55:1454–60.
    1. Naismith RT, Xu J, Klawiter EC, et al. Spinal cord tract diffusion tensor imaging reveals disability substrate in demyelinating disease. Neurology 2013;80:2201–9.
    1. Grossman RI, Barkhof F, Filippi M. Assessment of spinal cord damage in MS using MRI. J Neurol Sci 2000;172:S36–9.
    1. Grussu F, Schneider T, Kearney H, et al. Towards Spinal Cord Microstructure Mapping with the Neurite Orientation Dispersion and Density Imaging. In: 21st Annual Meeting of the International Society for Magnetic Resonance in Medicine, 2013, 2095.
    1. Wu C, Zhu J, Baeslack J, et al. Longitudinal PET imaging for monitoring myelin repair in the spinal cord. Ann Neurol 2013;9:1–32.
    1. The Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis. Arch Neurol 2008;65:727–32.
    1. Balcer LJ. Optic neuritis. N Engl J Med 2006;354:1273–80.
    1. Toussaint D, Perier O, Verstappen A, et al. Toussaint 1983.pdf. J Clin Neuroophthalmol 1983;3:211–20.
    1. Plant G, Kermode A, Turano G, et al. Symptomatic retrochiasmal lesions in multiple sclerosis: clinical features, visual evoked potentials, and magnetic resonance imaging. Neurology 1992;42:68–76.
    1. Breij ECW, Brink BP, Veerhuis R, et al. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol 2008;63:16–25.
    1. Connick P, Kolappan M, Crawley C, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol 2012;11:150–6.
    1. Frohman EM, Fujimoto JG, Frohman TC, et al. Optical coherence tomography: a window into the mechanisms of multiple sclerosis. Nat Clin Pract Neurol 2008;4:664–75.
    1. Petzold A, de Boer JF, Schippling S, et al. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol 2010;9:921–32.
    1. Saidha S, Syc SB, Durbin MK, et al. Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness. Mult Scler 2011;17:1449–63.
    1. Henderson APD, Altmann DR, Trip SA, et al. Early factors associated with axonal loss after optic neuritis. Ann Neurol 2011;70:955–63.
    1. Klistorner A, Garrick R, Barnett MH, et al. Axonal loss in non-optic neuritis eyes of patients with multiple sclerosis linked to delayed visual evoked potential. Neurology 2013;80:242–5.
    1. Barker GJ. Technical issues for the study of the optic nerve with MRI. J Neurol Sci 2000;172(Suppl):S13–6
    1. Johnson G, Miller DH, Macmanus D, et al. STIR sequences in NMR imaging of the optic nerve. Neuroradiology 1987;29:238–45.
    1. Trip S, Schlottmann PG, Jones SJ, et al. Optic nerve magnetization transfer imaging and measures of axonal loss and demyelination in optic neuritis. Mult Scler 2007;13:875–9.
    1. Richert ND, Ostuni JL, Bash CN, et al. Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis. Mult Scler 2001;7:49–58.
    1. Hickman SJ, Toosy AT, Jones SJ, et al. Serial magnetization transfer imaging in acute optic neuritis. Brain 2004;127:692–700.
    1. Inglese M, Ghezzi A, Bianchi S, et al. Irreversible disability and tissue loss in multiple sclerosis: a conventional and magnetization transfer magnetic resonance imaging study of the optic nerves. Arch Neurol 2002;59:250–5.
    1. Klistorner A, Chaganti J, Garrick R, et al. Magnetisation transfer ratio in optic neuritis is associated with axonal loss, but not with demyelination. Neuroimage 2011;56:21–6.
    1. Naismith RT, Xu J, Tutlam NT, et al. Diffusion tensor imaging in acute optic neuropathies: predictor of clinical outcomes. Arch Neurol 2012;69:65–71.
    1. Naismith RT, Xu J, Tutlam NT, et al. Radial diffusivity in remote optic neuritis discriminates visual outcomes. Neurology 2010;74:1702–10.
    1. Trip SA, Wheeler-Kingshott C, Jones SJ, et al. Optic nerve diffusion tensor imaging in optic neuritis. Neuroimage 2006;30:498–505.
    1. Samson RS, Kolappan M, Thomas DL, et al. Development of a high-resolution fat and CSF- suppressed optic nerve DTI protocol at 3T : application in multiple sclerosis. Funct Neurol 2013;28:93–100.
    1. Barker GJ. Diffusion-weighted imaging of the spinal cord and optic nerve. J Neurol Sci 2001;186:S45–9.
    1. Xu J, Sun S, Naismith RT, et al. Assessing optic nerve pathology with diffusion MRI : from mouse to human. NMR Biomed 2008;186:928–40.
    1. Wheeler-kingshott CAM, Parker GJM, Symms MR, et al. ADC mapping of the human optic nerve : increased resolution, coverage, and reliability with CSF-suppressed ZOOM-EPI. Magn Reson Med 2002;47:24–31.
    1. Hickman SJ, Wheeler-kingshott CAM, Jones SJ, et al. Optic nerve diffusion measurement from diffusion-weighted imaging in optic neuritis. Am J Neuroradiol 2005;26:951–6.
    1. Altmann DR, Button T, Schmierer K, et al. Sample sizes for lesion magnetisation transfer ratio outcomes in remyelination trials for multiple sclerosis. Mult Scler Relat Disord 2013:1–7.
    1. Schmierer K, Tozer DJ, Scaravilli F, et al. Quantitative magnetization transfer imaging in postmortem multiple sclerosis brain. J Magn Reson Imaging 2007;26:41–51.
    1. Davies GR, Altmann DR, Hadjiprocopis a, et al. Increasing normal-appearing grey and white matter magnetisation transfer ratio abnormality in early relapsing-remitting multiple sclerosis. J Neurol 2005;252:1037–44.
    1. Van den Elskamp IJ, Knol DL, Vrenken H, et al. Lesional magnetization transfer ratio: a feasible outcome for remyelinating treatment trials in multiple sclerosis. Mult Scler 2010;16:660–9.
    1. Brown RA, Narayanan S, Arnold DL. Segmentation of magnetization transfer ratio lesions for longitudinal analysis of demyelination and remyelination in multiple sclerosis. Neuroimage 2013;66C:103–9.
    1. Goldschmidt T, Antel J, König FB, et al. Remyelination capacity of the MS brain decreases with disease chronicity. Neurology 2009;72:1914–21.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다